Cantor Fitzgerald Weighs in on AXSM FY2025 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Axsome Therapeutics in a research note issued on Tuesday, February 11th. Cantor Fitzgerald analyst C. Duncan anticipates that the company will post earnings of ($2.88) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $121.00 price objective on the stock. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($4.70) per share.

A number of other research firms have also recently issued reports on AXSM. Needham & Company LLC reiterated a "buy" rating and issued a $133.00 target price on shares of Axsome Therapeutics in a research report on Monday, February 10th. Leerink Partners boosted their target price on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the stock an "outperform" rating in a research note on Monday, February 10th. HC Wainwright reiterated a "buy" rating and issued a $190.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, February 11th. Robert W. Baird boosted their price objective on Axsome Therapeutics from $112.00 to $116.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 13th. Finally, StockNews.com upgraded Axsome Therapeutics from a "sell" rating to a "hold" rating in a research report on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $147.13.

Axsome Therapeutics Price Performance

AXSM traded down $0.53 during trading on Thursday, hitting $131.15. 1,064,118 shares of the stock traded hands, compared to its average volume of 954,569. Axsome Therapeutics has a twelve month low of $64.11 and a twelve month high of $134.18. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. The business has a 50 day moving average price of $97.84 and a 200 day moving average price of $93.37. The company has a market cap of $6.36 billion, a price-to-earnings ratio of -20.08 and a beta of 1.05.

Insider Buying and Selling

In related news, CFO Nick Pizzie sold 3,000 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the sale, the chief financial officer now owns 42,187 shares of the company's stock, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 22.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Axsome Therapeutics

Several large investors have recently added to or reduced their stakes in AXSM. Assetmark Inc. acquired a new position in Axsome Therapeutics during the 4th quarter worth approximately $52,000. R Squared Ltd bought a new stake in Axsome Therapeutics during the 4th quarter valued at $64,000. Aquatic Capital Management LLC bought a new position in shares of Axsome Therapeutics in the fourth quarter valued at approximately $76,000. KBC Group NV grew its holdings in shares of Axsome Therapeutics by 40.5% in the fourth quarter. KBC Group NV now owns 1,336 shares of the company's stock valued at $113,000 after acquiring an additional 385 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Axsome Therapeutics by 22.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company's stock valued at $156,000 after acquiring an additional 318 shares in the last quarter. Institutional investors and hedge funds own 81.49% of the company's stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.